Direct analysis: Microbot Medical (NASDAQ: MBOT) and Replimune Group (NASDAQ: REPL)

0

Microbot Medical (NASDAQ:MBOT – Get Rating) and Replimune Group (NASDAQ:REPL – Get Rating) are both small-cap medical companies, but which is the better stock? We’ll compare the two companies based on valuation strength, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Benefits and evaluation

This table compares the revenue, earnings per share, and valuation of Microbot Medical and Replimune Group.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
medical microbot N / A N / A -$11.31 million ($1.42) -4.07
Replimune Group N / A N / A -80.87 million dollars ($2.07) -7.12

Replimune Group is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares the net margins, return on equity and return on assets of Microbot Medical and Replimune Group.

Net margins Return on equity return on assets
medical microbot N / A -60.58% -54.85%
Replimune Group N / A -23.03% -20.99%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Microbot Medical and Replimune Group, as provided by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
medical microbot 0 0 0 0 N / A
Replimune Group 0 0 6 0 3.00

Replimune Group has a consensus target price of $48.33, indicating an upside potential of 227.91%. Considering Replimune Group’s likely higher upside, analysts clearly believe that Replimune Group is more favorable than Microbot Medical.

Insider and Institutional Ownership

11.5% of Microbot Medical shares are held by institutional investors. Comparatively, 75.4% of Replimune Group shares are held by institutional investors. 10.8% of Microbot Medical stock is held by insiders of the company. By comparison, 40.3% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers, and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Microbot Medical has a beta of 3.98, suggesting its stock price is 298% more volatile than the S&P 500. In comparison, Replimune Group has a beta of 2.29, suggesting its stock price is 129% more volatile than the S&P 500.

Summary

Replimune Group beats Microbot Medical on 6 of the 10 factors compared between the two stocks.

About Microbot Medical (Get a rating)

Microbot Medical Inc., a preclinical medical device company, engages in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its micro-robotic technologies ViRob, TipCAT, CardioSert and Liberty, is developing a self-cleaning shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a portfolio of multi-generation pipelines. It has 42 issued/cleared patents and 23 pending patent applications worldwide. The company has entered into a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.

About Replimune Group (Get a rating)

Replimune Group LogoReplimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates to activate the immune system against cancer. The Company’s lead product candidate is RP1, a replication-selective version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and which is the subject of phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in phase I clinical trials for an anti-CTLA-4 antibody-like protein to block immune response inhibition otherwise caused by CTLA-4; and RP3 which is in Phase I clinical trials to express immune activation proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.



Get news and reviews for Microbot Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Microbot Medical and related companies with MarketBeat.com’s FREE daily newsletter.

Share.

About Author

Comments are closed.